Table: Takeda Pharma -Q1 group results (IFRS)

Takeda Pharmaceutical

30/07/2026 07:31

   Jul 30 (Reuters)- 
              Takeda Pharmaceutical Co. Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Jun 30, 2026        Jun 30, 2025     Mar 31, 2027 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales             1.22 trln           1.11 trln        4.64 trln  
                   (+10.2 pct)         (-8.4 pct)       (+3.0 pct)  
  Operating          201.42              184.57           420.00    
                   (+9.1 pct)          (+11.0 pct)                  
  Pretax             162.72              150.63           252.00    
                   (+8.0 pct)          (+10.3 pct)                  
  Net                113.20              124.24           166.00    
                   (-8.9 pct)          (+30.4 pct)                  
  EPS Basic         71.65 yen           79.40 yen       104.26 yen  
  EPS Diluted       70.54 yen           78.23 yen                   
  Ann Div                              200.00 yen       204.00 yen  
  -Q2 Div                              100.00 yen       102.00 yen  
  -Q4 Div                              100.00 yen       102.00 yen  
 
  NOTE - Takeda Pharmaceutical Co. Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4502.T